



1627
BOX 500
PATENT
TECH CENTER 1600
JAN 07 2002
RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

CERTIFICATE OF MAILING

I hereby certify that this RESPONSE and the documents referred to as enclosed therein are being deposited with the United States Postal Service on the date indicated below with sufficient postage as First Class Mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.

Nancy Malsich
Nancy Malsich

11/2/01

Date of Deposit

Applicant: Wong, et al.)
Serial No.: 09/077,712) Group Art Unit: 1627
Filed: July 9, 1999) Examiner: T. Prasthofer
Title: HIV PROTEASE INHIBITORS)
)
) Our Ref.: TSRI 482.1
)

**RESPONSE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO
ACID SEQUENCE DISCLOSURES (37 CFR §1.821-1.825)**

Assistant Commissioner for Patents
ATTN: BOX SEQUENCE
Washington, D.C. 20231

Dear Sir:

In response to the enclosed copy of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures Under 37 CFR §1.821-1.825 mailed October 2, 2001, enclosed is a Sequence Listing on paper copy, made in accordance with 37 CFR §1.821 - §1.825. Also enclosed is the Sequence Listing in computer readable form, submitted as required by 37 CFR §1.821(e), on which the Sequence Listing is labeled 482.1/SCR 2025P.


Applicants respectfully request entry of the Sequence Listing and computer readable copy thereof.

I hereby state that the content of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 CFR §1.821(a) through (c) and (e), respectively, are the same and include no new matter.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that making willful false statements and the like is punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Nov 2, 2001

Date



Donald G. Lewis, Reg. No. 28,636

THE SCRIPPS RESEARCH INSTITUTE
10550 North Torrey Pines Road
Mail Drop TPC-8
La Jolla, California 92037
(858) 784-2937